Building on a turn toward more equity investments in the second quarter of this year, the top 50 hedge funds boosted their equity positions by nearly 3% in the third quarter.
With the Republicans now set to control both Congress and the White House, many on Wall Street feel that there could be far less scrutiny on drug pricing.
The top analyst upgrades, downgrades and initiations seen on Monday morning include AbbVie, Chevron, Home Depot, Nike, Qualcomm and VMware.
Alkermes' positive Phase 3 results for its novel antidepressant is serving as a rising tide — a storm surge even — for many biotech companies in the depression space.
Tobira Therapeutics shares skyrocketed on Tuesday after Allergan announced that it will acquire the company.
Chris Lange The goal of Allergan’s bid for Vitae Pharmaceuticals is to bolster its dermatology product pipeline, and Vitae shareholders appear happy to oblige.
Chris Lange In one of the longest running bidding wars in recent times, Pfizer has finally reeled in cancer-drug maker Medivation.
The top analyst upgrades, downgrades and initiations seen on Friday morning include AK Steel, Allergan, ArcelorMittal, Symantec, Teck Resources, US Steel, Emerson and Hormel.
Credit Suisse has run bullish and bearish scenarios for what the firm feels is a reasonable upside and downside for each of its large cap pharmaceutical stocks.
Allergan reported mixed second-quarter 2016 results and announced share buybacks before markets opened Monday morning.
Teva Pharmaceutical Industries is scheduled to release its second-quarter financial results before the markets open on Thursday.
The top analyst upgrades, downgrades and initiations seen on Monday morning include Allergan, General Electric, Hewlett Packard Enterprise, Southwest Airlines and Williams Companies.
Lucky for Teva Pharmaceuticals, interest rates on all kinds of debt have never been lower in recorded human history, and they keep getting lower even beyond basic logic.
Even though the trend toward generic drugs is only likely to grow, the drug price pressures hanging over the sector also hurt most generic drug makers.
Ever since the infamous Hillary Clinton tweet about pharmaceutical drug pricing, the biotech and specialty pharmaceutical stocks have taken a huge beating. In some cases, the markets have knocked valuations down into…
